Skip to main content

Table 2 Results of the benchtop and the freeze/thaw stability studies

From: Homogeneous liquid–liquid microextraction coupled with HPLC/DAD for determination of nirmatrelvir and ritonavir as COVID-19 combination therapy in human plasma

 

Amount added

(ng/mL)

Amount found

(ng/mL)

% Found ± RSD

Bench top

 NIRMA

3000

3345

111.51 ± 6.42

18,000

20,263

112.57 ± 6.24

 RITONA

600

663

110.54 ± 4.81

18,000

18,711

103.95 ± 0.611

Freeze and thaw 1st Cycle

  

 NIRMA

3000

3302

110.08 ± 9.26

18,000

19,930

110.72 ± 2.68

 RITONA

600

606

100.93 ± 6.29

18,000

19,667

109.26 ± 1.55

Freeze and thaw 2nd cycle

 NIRMA

3000

3344

111.47 ± 6.67

18,000

18,258

101.44 ± 7.96

 RITONA

600

683

113.87 ± 4.1

18,000

17,696

98.31 ± 7.48

Freeze and thaw 3rd cycle

 NIRMA

3000

3239

107.97 ± 4.87

18,000

20,561

114.23 ± 5.13

 RITONA

600

681

113.45 ± 7.52

18,000

19,540

108.58 ± 1.89